Xeris Biopharma Holdings, Inc. Stock price Nasdaq
Equities
XERS
US98422L1070
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 184M | Sales 2025 * | 219M | Capitalization | 287M |
---|---|---|---|---|---|
Net income 2024 * | -55M | Net income 2025 * | -27M | EV / Sales 2024 * | 1.55 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.31 x |
P/E ratio 2024 * |
-5.3
x | P/E ratio 2025 * |
-11.1
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.13% |
Latest transcript on Xeris Biopharma Holdings, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 04-12-31 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 21-10-04 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
1st Jan change | Capi. | |
---|---|---|
+9.16% | 45.97B | |
+53.69% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |